Novartis Stock Gets Weaker EPS Estimate from Zacks Research

Novartis AG (NYSE:NVS – Free Report) – Stock analysts at Zacks Research lowered their FY2028 earnings estimates for Novartis in a research report issued on Tuesday, November 10th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $10.62 for the year, down from their previous forecast of $10.69. The consensus estimate for Novartis’ current full-year earnings is $9.10 per share.

Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business earned $2.25 earnings per share.

A number of other equities analysts have also recently weighed in on the stock. Deutsche Bank cut shares of Novartis from a “hold” rating to a “sell” rating in a research report on Friday, October 30th. Bank of America reissued a “buy” rating on shares of Novartis in a research report on Tuesday, September 8th. Weiss Ratings cut Novartis from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. DZ Bank assumed coverage on Novartis in a research report on Wednesday, October 28th. They set a “hold” rating for the company. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis in a research report on Sunday, August 9th. Six research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $152.25.

Read Our Latest Report on Novartis

Novartis Stock Performance

Shares of NVS stock opened at $160.59 on Thursday. The firm’s 50 day moving average price is $149.13 and its 200-day moving average price is $152.60. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.70 and a current ratio of 0.88. Novartis has a one year low of $123.24 and a one year high of $170.46. The firm has a market cap of $306.42 billion, a P/E ratio of 18.03, a P/E/G ratio of 2.93 and a beta of 0.40.

Institutional Trading of Novartis

Hedge funds have recently made changes to their positions in the business. Empowered Funds LLC boosted its stake in shares of Novartis by 51.7% in the third quarter. Empowered Funds LLC now owns 97,449 shares of the company’s stock valued at $13,893,000 after purchasing an additional 33,225 shares during the period. Kovack Advisors Inc. grew its holdings in shares of Novartis by 55.6% in the third quarter. Kovack Advisors Inc. now owns 3,360 shares of the company’s stock valued at $476,000 after purchasing an additional 1,200 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in Novartis by 15.4% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 51,275 shares of the company’s stock worth $7,310,000 after buying an additional 6,857 shares during the period. Insigneo Advisory Services LLC increased its stake in Novartis by 6.4% during the 3rd quarter. Insigneo Advisory Services LLC now owns 6,617 shares of the company’s stock worth $943,000 after buying an additional 400 shares during the period. Finally, Mosaic Family Wealth Partners LLC lifted its holdings in Novartis by 7.9% during the 3rd quarter. Mosaic Family Wealth Partners LLC now owns 4,113 shares of the company’s stock worth $586,000 after buying an additional 301 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Novartis

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Featured Articles

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.